News

Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know
Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...
Novo Nordisk halts Wegovy sales on Hims & Hers, claiming "deceptive marketing" practices
Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...
Novo, Hims & Hers engage in war of words after Wegovy deal falls apart
Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...
Hims & Hers Stock Tumbles as Novo Nordisk Ends Its Wegovy Sales Deal. Can the Telehealth Giant Recover?
The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.
Long Island experts weigh in after Novo Nordisk ends deal with Hims & Hers over weight loss meds
Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...
Without GLP-1 Hims & Hers Is A $20s Per Share Stock -- Sell Call
Novo Nordisk ends partnership with Hims & Hers, causing a 35% plunge. With no near-term catalysts, learn why investors must ...
Hims & Hers Sued Over Wegovy Maker’s Exit, Record Stock Selloff
Hims & Hers Health Inc. investors have sued the telehealth provider days after Novo Nordisk A/S announced it was ending the ...
Forbes4d
HIMS Stock To $25?
The collaboration between HIMS and Novo Nordisk, which began in April 2025, was supposed to be a game-changer for the telehealth company. The partnership promised direct access to Wegovy, Novo ...